Anthony H Goldstone
Affiliation: University College London
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyAdele K Fielding
Royal Free and University College London Medical School, and Christie Hospital National Health Service Trust, Manchester, UK
Blood 109:944-50. 2007..Prevention of recurrence is the best strategy for long-term survival in this disease...
- Clinical use of rituximab in haematological malignanciesI Avivi
University College London Hospital, UK
Br J Cancer 89:1389-94. 2003..Rituximab has also shown activity in other B-cell disorders such as chronic lymphocytic leukaemia. The full potential of this immunotherapeutic agent remains to be defined in ongoing and future clinical trials...
- The allogeneic effect in non-Hodgkin's lymphomaAnthony H Goldstone
North London Cancer Network, 6th Floor, Rosenheim Wing, 25 Grafton Way, London WC1E 6DB, UK
Leuk Lymphoma 44:S91-7. 2003..However, treatment will be improved by optimizating conditioning regimens and a better understanding of patient selection criteria and the immune processes involved in graft-vs.-host disease and GVT...
- Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimensKirit M Ardeshna
Department of Haematology, University College London Hospitals, London, UK
Br J Haematol 130:363-72. 2005..This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored...
- Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experienceJonathan Sive
Department of Haematology, University College London Hospital, London, UK
Leuk Lymphoma 53:2397-404. 2012..An ACU/hotel-based treatment model can be safely used for a wide variety of cancers and treatments, expanding hospital treatment capacity, and freeing up inpatient beds for those patients requiring them...
- Redefining transplant in acute leukemiaRob Sellar
Department of Haematology, University College London Hospital, UK
Curr Treat Options Oncol 12:312-28. 2011..The importance of enrolling patients into suitable prospective clinical trials cannot be overstated...
- Conventional allograft and autograft in low grade lymphomaIrit Avivi
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, P O Box 9602, Haifa 31096, Israel
Best Pract Res Clin Haematol 18:113-28. 2005..However, data is still limited and follow-up in the majority of studies is relatively short, highlighting the need for longer follow-up to establish the role of reduced intensity SCT in low grade lymphoma...
- Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs
Department of Haematology, Royal Free and University College London, UK
Lancet 365:1934-41. 2005..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
- Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Jacob M Rowe
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel
Blood 106:3760-7. 2005..However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor...
- Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993Hillard M Lazarus
Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
Blood 108:465-72. 2006..03) for those without. CNS leukemia in adult ALL is uncommon at diagnosis. Adult Ph-negative ALL patients, however, can attain long-term disease-free survival using SCT as well as conventional chemotherapy...
- Long-term results of the MRC AML10 trialAlan K Burnett
Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom
Clin Adv Hematol Oncol 4:445-51. 2006
- Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman
Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton General Hospital, Southampton, UK
Blood 109:3189-97. 2007....
- Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs
Department of Haematology, Royal Free and University College, London, UK
Br J Haematol 139:70-80. 2007....
- In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/Anthony H Goldstone
North London Cancer Network, University College London Hospitals, London, United Kingdom
Blood 111:1827-33. 2008..There is no evidence that a single autologous transplantation can replace consolidation/maintenance in any risk group. This study is registered at http://clinicaltrials.gov as NCT00002514...
- High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphomaAdrian J C Bloor
Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
Biol Blood Marrow Transplant 14:50-8. 2008..These data support the existence of a clinically significant graft-versus-tumor effect in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT...
- Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenRonjon Chakraverty
Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, United Kingdom
Blood 99:1071-8. 2002..In summary, a nonmyeloablative regimen incorporating in vivo CAMPATH-1H is effective in promoting durable engraftment in most patients and in reducing the risk of severe GVHD following matched unrelated donor transplantation...
- Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow TransplantationStephen P Robinson
Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, London, United Kingdom
Blood 100:4310-6. 2002..A longer period of follow-up is required to determine the benefit of DLI and the graft-versus-lymphoma effect...
- Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignanciesKatharine Branson
CR UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
J Clin Oncol 20:4022-31. 2002..The aim of the current study was to evaluate the safety and efficacy of sibling, HLA-matched, nonmyeloablative allogeneic SCT with donor lymphocyte infusion (DLI) in patients with lymphoid malignancy after failure of autologous SCT...
- Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersJose A Perez-Simon
Department of Hematology, Hospital Universitairo de Salamanca, Paseo de San Vicente s n, 37007 Salamanca, Spain
Blood 100:3121-7. 2002..Patients receiving alemtuzumab often required DLIs to achieve similar tumor control but the incidence of GVHD was not significantly increased after DLI...
- Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortalitySuparno Chakrabarti
Department of Haematology, Birmingham Heartlands Hospital, University College Hospital, London, UK
Br J Haematol 119:1125-32. 2002....
- Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant RegistriesElisabeth Vandenberghe
Department of Haematology, St James Hospital, Dublin, Ireland
Br J Haematol 120:793-800. 2003..99 times (95% CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR...
- Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trialNorbert Schmitz
Department of Internal Medicine II, University of Kiel, Kiel, Germany
Lancet 359:2065-71. 2002..We aimed to compare this treatment with conventional aggressive chemotherapy without stem-cell transplantation (Dexa-BEAM)...
- Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activityKarl S Peggs
Department of Haematology, University College London Hospitals, London, United Kingdom
Biol Blood Marrow Transplant 9:257-65. 2003..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
- Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesKarl S Peggs
Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
Blood 103:1548-56. 2004....
- The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trialAlan K Burnett
Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, Wales, UK
Br J Haematol 118:385-400. 2002..This trial found no survival advantage in children, patients over 35 years or good-risk disease...
- Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimenKarl S Peggs
Blood 99:4642-3; author reply 4643-4. 2002
- High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionSuparno Chakrabarti
Department of Haematology, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom
Blood 99:4357-63. 2002..The use of Campath-1H appeared to be associated with a low incidence of GVHD but a high incidence of CMV infections and prolonged immune paresis...
- A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatmentAlan K Burnett
Department of Haematology, Wales School of Medicine, Cardiff University, Cardiff, United Kingdom
Cancer 109:1114-24. 2007..The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach...
- Development of squamous cell carcinoma of the skin during induction chemotherapy for acute myeloid leukemiaPanagiotis D Kottaridis
Leuk Lymphoma 43:459-60. 2002
- Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumabIrit Avivi
Department of Haematology, University College Hospital, London, UK
Biol Blood Marrow Transplant 10:186-94. 2004....
- Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myelomaCharalampia Kyriakou
Department of Haematology, University College London Hospitals, London, UK
Br J Haematol 129:763-70. 2005..We conclude that the CDT regimen is safe, well tolerated and effective in patients with relapsed and refractory myeloma...
- Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris
Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
Blood 102:404-6. 2003..Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P =.005), and median absolute CD4 counts higher than 200 x 106/L were delayed until 9 months after transplantation...
- Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infectionKarl S Peggs
Department of Haematology, University College London, London, United Kingdom
Biol Blood Marrow Transplant 9:198-205. 2003....
- Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effectsShirley D'Sa
Department of Haematology, University College London Hospitals NHS Trust, London, UK
Br J Haematol 125:756-65. 2004..We conclude that ESHAP has acceptable toxicity and efficient stem cell mobilizing capability, effectively cytoreduced this chemoresistant group of patients, and did not appear to adversely affect transplant outcome...
- Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemiaChristine J Harrison
Leukaemia Research Fund Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton, UK
Br J Haematol 125:552-9. 2004..Thus cytogenetics, or at least a clear definition of the modal chromosome number, is essential at diagnosis in order to stratify patients with hypodiploidy into the appropriate risk group for treatment...